Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.89 | N/A | -6.42% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.89 | N/A | -6.42% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a commitment to advancing their pipeline. They acknowledged the challenges but remain focused on long-term goals.
Management highlighted ongoing efforts in research and development.
They emphasized the importance of upcoming clinical trials.
PTC Therapeutics reported a wider-than-expected loss per share, which may raise concerns among investors. However, the stock rose by 2.79%, likely due to positive sentiment around their ongoing research initiatives. The lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KIMBERLY CLARK CORP
Oct 25, 2021